Andrea F. Wainer

October 12, 2026

Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.

October 16, 2026

Analog Devices Rises While Market Falls, Receives Rating Upgrade. Analog Devices shares climbed while the broader market slipped, showing resilience in the semiconductor space. Analysts upgraded the stock, reflecting confidence in its product mix and growth prospects. The company remains competitive against peers, and its price has moved above key support levels with a recent volume spike.

October 16, 2026

Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.